TAITUNG, TAIWAN – Media OutReach – 18 November 2020 – The 2020 Taiwan Open of Surfing is entering its 10th anniversary this year. The five-day competition will be held in Jinzun Harbor in Taitung County during 18-22 November. While most international surfing contests this year have been canceled or postponed until further notice due to the pandemic, Taiwan has excelled at beating COVID-19 with minimal disruption to daily life. Since the outbreak, Taitung’s status of zero coronavirus case contributes to Magistrate April Yao’s decision to proceed with this year’s Taiwan Open of Surfing as scheduled. The winning prize of 800,000 New Taiwan Dollar (about US$26,600) marks the highest accolade in Taiwan’s surfing competition history. With this, the event organizer hopes to boost publicity for the Taiwan Open of Surfing and continue to share this special event with the world.
The 2020 Taiwan Open of Surfing starts in Taitung today – Surfs Up
Taitung County bordering of the Pacific Ocean sets a slow pace for locals and visitors to enjoy its mild climate and fresh air. These factors along with consistent surf make Taitung the perfect location to hold a surfing competition. The Taitung County Government has collaborated with the World Surfing League (WSL) to host the Taiwan Open of Surfing in Jinzun since 2011. This international surfing competition has attracted over 30 different countries’ top competitors over the years. This year the contest will continue to cooperate with the WSL as they have agreed to provide remote support to ensure the event adheres to the strict WSL international tournament standards – from competition pre-planning, scoring, live broadcasting, etc. Once the world recovers from COVID-19, Taitung hopes to continue with the WSL to host this grand world-class surfing event long into the future.
The Taitung County Government has been actively promoting various ocean activities and events – such as beach cleanups, surfing lessons, marine life education, local hand-craft markets, kite surfing and windsurfing demonstrations, and many more ocean-themed activities to encourage the general public’s participation. All participants can experience first-hand Taitung’s unique allure and its picturesque surroundings. Official website: https://www.taiwanopenofsurfing.org/tw
Spleeff Announces New Flavor-Rich Hemp Vapes Now Available on their Web Store
CHICAGO, Dec. 4, 2020 /PRNewswire/ — Spleeff today announced an industry-leading full selection of flavor-rich hemp vapes on their online web store. The hemp vapes, which contain no nicotine, were created to provide all the enjoyment that customers of Spleeff have come to expect with the Spleeff natural flavor hemp vape, but with deliciously flavored aromas.
In addition to the popular pure, natural hemp vape, customers can now purchase four additional flavors including: Butter Rum, Vanilla Butternut, Crème de Menthe, and Mango. These new flavors further enhance the pleasures of vaping superior hemp with the introduction of great tasting flavor and delightful aromas.
“Our customers have been asking for a wider selection of flavors for a while now. They all enjoy our high-quality hemp vapes but some customers wanted us to bring a wider selection of flavors to not only eliminate the social stigma that still exists when people get a whiff of hemp, but to also provide to smoother and more pleasant aroma for them. We think we knocked it out of the park,” said Valerie Cornwall, Vice President of Marketing at Spleeff.
All the hemp vapes are available in 510 compatible cartridges and as part of the launch, customers will get 50% of the purchase price for a new the Spleeff vape devices. The new flavors are also available in discounted group packs called “flights”, which include free shipping. Flights are available as three packs and five packs of the various flavors.
Hemp, defined as cannabis containing less than 0.3% THC, was removed from the Schedule 1 controlled substances list making it an ordinary agricultural commodity in The United States, with the passage of the 2018 United States farm bill. THC is the principal psychoactive cannabinoid in cannabis. All Spleeff hemp vape conform to the farm bill specifications and contain non-detectable amounts of THC.
Spleeff is committed to responsible vaping with several layers of security and checks to ensure that not only is anyone under 21 years old prevented from purchasing the vape products, but also to ensures that customers older than 21 are vaping responsibly.
Spleeff is an online hemp brand licensed by the state of Illinois as a Hemp processor. Spleeff leads the hemp market in innovation and quality with its selection of hemp vapes. Spleeff's employees are committed to making the best hemp vapes in the world and creating the best experience for our customers.
View original content to download multimedia:http://www.prnewswire.com/news-releases/spleeff-announces-new-flavor-rich-hemp-vapes-now-available-on-their-web-store-301186312.html
Marizyme, Inc. Expands Executive Team, Board of Directors
JUPITER, Fla., Dec. 4, 2020 /PRNewswire/ — Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has expanded the company's executive team and board of directors with three new appointments.
Steven Brooks, M.D., MBA, FACC, has been named EVP of Medical and Regulatory Affairs, Chief Medical Officer for Marizyme. Dr. Brooks brings more than 20 years of experience supporting the commercialization of medical innovation, including medical devices, mHealth, drugs, biologics and combination products, to this role.
Donald Very, Ph.D., has also joined the executive management team as EVP, Research & Development. Dr. Very has more than 30 years of experience in all phases of pharmaceutical and diagnostic assay research and device development, including performance validation, clinical trial design and implementation, and regulatory approvals.
William Hearl, Ph.D., an experienced and successful life science entrepreneur who is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities, has been named an Independent Member of Marizyme's Board of Directors.
“Drs. Brooks and Very will provide Marizyme with a wealth of scientific, regulatory and capital markets expertise, all of which is critical as the company seeks to grow its life science assets and elevate its financial position,” said Dr. Neil J. Campbell, Marizyme's CEO and President and a Member of its Board of Directors. “Dr. Brooks and Dr. Very will provide experience and leadership in building Marizyme's pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space.”
Mr. James Sapirstein, Marizyme's Executive Chairman, said, “Dr. Hearl's track record of brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities will be invaluable in bolstering Marizyme's shareholder value.”
Dr. Hearl, Independent Member of Marizyme's Board of Directors, commented, “I am excited to join Marizyme's board and work to support the company as it builds the promising suite of acute care therapies.”
Steven Brooks, M.D., MBA, FACC – EVP of Medical and Regulatory Affairs, Chief Medical Officer
Steven Brooks, M.D., MBA, FACC, has more than 20 years of experience supporting the commercialization of medical innovation, including medical devices, mHealth, drugs, biologics and combination products. He was the Principle of Brooks Medtech, LLC, a medical technology consulting firm. Dr. Brooks' interests include evidence development, clinical trial design and execution, regulatory and reimbursement strategy and healthcare market strategy.
Dr. Brooks was previously an interventional cardiologist at University of Maryland Medical Center and private practice. He also served as a medical officer within FDA's CDRH in the Division of Cardiovascular Devices.
Dr. Brooks has held positions with the life science consulting firms NDA Partners, Popper & Company, and Sage Growth Partners. He is CMO for Global Interconnect and previously held the positions of CMO for Cardiocube, LLC and VP of Regulatory Affairs and Health Economics for Ablative Solutions.
Dr. Brooks earned his M.D. at the University of Pittsburgh School of Medicine, and his Residency in Cardiology and Interventional Cardiology Fellowships at University of Pittsburgh Medical Center. He received his MBA from the Johns Hopkins Carey School of Business in the Business of Medicine Program, and his B.A. at Duke University.
Donald Very, Ph.D. – EVP, Research & Development
Donald Very, Ph.D., has more than 30 years of device, diagnostic and, pharmaceutical compound/assay development and performance qualification experience in such diverse clinical areas as oncology, infectious disease, cardiovascular and, metabolic disease. Dr. Very has extensive experience in all phases of pharmaceutical and diagnostic assay research and device development, performance validation, clinical trial design and implementation, and regulatory approval.
Dr. Very previously served as Senior Vice President of Mosaigen, a global science & technology development corporation; and President, CEO, and Founder of Naviter Bioanalytics, LLC, a private consulting firm specializing in technological due diligence, bioanalytical method development, performance qualification, and regulatory approval.
Dr. Very also previously served in senior executive and scientific positions at Helomics Corporation, Ancera, Inc., the Institute for Bioanalytics, LLC (IBA), and the Bayer Corporation. Dr. Very began his career as a researcher and supervisor of laboratories affiliated with the U.S. Army Medical Research Unit in the Republic of Korea.
Dr. Very is a frequently invited speaker at national and international scientific symposia. He received his B.S. degree in Biology from the University of Notre Dame, his M.S. degree in Biology from the University of Texas at San Antonio, and his Ph.D. in Microbiology/Immunology from Boston University.
Board of Directors Appointment
William Hearl, Ph.D. – Independent Member of Board of Directors
William Hearl, Ph.D., the founder of Immunomic Therapeutics, Inc. (ITI), is an experienced and successful life science entrepreneur who is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities.
Dr. Hearl founded ITI in 2006 to commercially develop LAMP technology, which was sub-licensed to Geron Corporation and later led to license agreements valued at $300+ million with Japan-based Astellas for next generation allergy vaccines based on the LAMP platform.
Dr. Hearl is also a founder of Capital Genomix, Inc., a Maryland-based biomarker and drug discovery company, and served as its CEO and Chief Scientific Officer. He was instrumental in CGI's acquisition of the Dynex Technologies division of Thermo Scientific, which was subsequently divested and yielded a remarkable tenfold return to the company.
Dr. Hearl is also responsible for the acquisition and development of the core technologies of Capital Genomix, the GeneSystem320™ and the ImmunoMouse™.
Dr. Hearl began his career as a bench scientist at Electro-Nucleonics, Inc., where he developed blood-based diagnostics for HIV, HTLV-I and Hepatitis C. He later directed the immunodetection group at Life Technologies and became the director of research and development at Kirkegaard & Perry Laboratories, Inc.
Dr. Hearl earned his Ph.D. in biochemistry from the University of Tennessee and B.S. from East Tennessee State University.
About Marizyme, Inc.
Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage, leading to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase® platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com.
This press release may contain certain forward-looking statements, including those relating to the Marizyme's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable, and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identified using forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, including those risks set forth in the Company's risk factor disclosure in the reports that Marizyme files with the Securities and Exchange Commission (SEC File No. 000-53223), uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Marizyme, Inc.
Lightwave Logic to Present to Industry Audience at ECOC Exhibition 2020
ENGLEWOOD, Colo., Dec. 4, 2020 /PRNewswire/ — Lightwave Logic, Inc. (OTCQB:LWLG), a technology platform company leveraging its proprietary electro-optic polymers to transmit data at higher speeds with less power, today announced that management has been invited to present at the ECOC Exhibition 2020 taking place virtually December 7-9, 2020.
Elected in 2019 to chair the committee for ECOC's Market Focus sessions at the International Exhibition, Dr. Michael Lebby will introduce the program on behalf of Lightwave Logic. The agenda brings together leading technologists from around the world who represent major players in the optical communications field. The full agenda covers three days of speakers.
Furthermore, Dr. Michael Lebby, Chief Executive Officer of Lightwave Logic, is scheduled to host a virtual presentation entitled, “EO Polymer modulator platform with enhanced stability at both 1.3um and 1.5um” during the event as follows:
ECOC Exhibition 2020 – Market Focus
Date: Tuesday, December 8, 2020
Time: 4:00 p.m. Central European Time
For more information or to register for the ECOC Exhibition 2020, please visit the event website at www.ecocexhibition.com.
About Lightwave Logic, Inc.
Lightwave Logic, Inc. (OTCQB:LWLG) is developing a platform leveraging its proprietary engineered electro-optic (EO) polymers to transmit data at higher speeds with less power. The Company's high-activity and high-stability organic polymers allow Lightwave Logic to create next-generation photonic EO devices, which convert data from electrical signals into optical signals, for applications in data communications and telecommunications markets. For more information, please visit the Company's website at www.lightwavelogic.com.
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, lack of available funding; general economic and business conditions; competition from third parties; intellectual property rights of third parties; regulatory constraints; changes in technology and methods of marketing; delays in completing various engineering and manufacturing programs; changes in customer order patterns; changes in product mix; success in technological advances and delivering technological innovations; shortages in components; production delays due to performance quality issues with outsourced components; those events and factors described by us in Item 1.A “Risk Factors” in our most recent Form 10-K and Form 10-Q; other risks to which our Company is subject; other factors beyond the Company's control.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lightwave-logic-to-present-to-industry-audience-at-ecoc-exhibition-2020-301186477.html
SOURCE Lightwave Logic, Inc.
GOTRAX Announces 2020 Holiday Sale on Limited Stock of Electric Scooters, Kick Scooter, E Bikes on GOTRAX.com and Amazon
DENVER, Dec. 4, 2020 /PRNewswire/ — Today, GOTRAX announces that customers can access these deals on their products for kids and...
Alliance Data Completes Acquisition of Bread®
COLUMBUS, Ohio, Dec. 4, 2020 /PRNewswire/ — Alliance Data Systems Corporation (NYSE: ADS), a leading provider of data-driven marketing, loyalty...
Pressure BioSciences Proposed Acquisition Partner Cannaworx, Inc. Announces December 2020 Launch Date for FDA Registered Immune Booster
SOUTH EASTON, Mass., Dec. 4, 2020 /PRNewswire/ — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in...
Marizyme, Inc. Expands Executive Team, Board of Directors
JUPITER, Fla., Dec. 4, 2020 /PRNewswire/ — Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to...
Greater Than: The Winner Of FIA Smart Driving Challenge 2020 Is Crowned
STOCKHOLM, Dec. 4, 2020 /PRNewswire/ — This week, Alexandre Stricher from France was named the winner of the FIA Smart Driving...
Argus launches US West Coast SAF price
HOUSTON, Dec. 4, 2020 /PRNewswire/ — Global energy and commodity price reporting agency Argus today launches a sustainable aviation fuel (SAF)...
CooTek to Participate in December and January Investor Conferences
SHANGHAI, Dec. 4, 2020 /PRNewswire/ — CooTek (Cayman) Inc. (NYSE: CTK) (“CooTek” or the “Company”), a fast-growing global mobile internet...
Restaurant Franchise Financing Rebounds to Pre-Pandemic Levels, MUFG Says
NEW YORK, Dec. 4, 2020 /PRNewswire/ — Financing for restaurant franchise operators in the large and middle-tier segments has mostly bounced...
TF Bank has successfully issued subordinated Tier 2 bonds
STOCKHOLM, Dec. 4, 2020 /PRNewswire/ — TF Bank AB (publ) (“TF Bank” or the “Company”) has issued subordinated Tier 2...
2020 Consumer Trends Drive Performance of Relaunched Pier 1 Imports and Dressbarn E-Commerce Sites on Black Friday/Cyber Monday
DALLAS, Dec. 4, 2020 /PRNewswire/ — The shift to online-shopping, as well as trends like the quest for comfort at home,...